Safpure Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-07-2024
- Paid Up Capital ₹ 0.10 M
as on 24-07-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
as on 24-07-2024
- Revenue 122.99%
(FY 2023)
- Profit 268.80%
(FY 2023)
- Ebitda -333.85%
(FY 2023)
- Net Worth 68.82%
(FY 2023)
- Total Assets 10.64%
(FY 2023)
About Safpure Lifesciences
The Corporate was formerly known as Primeayur Wellness Remedies Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 Cr.
Gaurav Khandelwal, Sourabh Khandelwal, Kali Khandelwal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232RJ2013PTC042203
- Company No.
042203
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Bijaynagar, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Safpure Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Khandelwal  | Director | 22-Apr-2013 | Current |
| Sourabh Khandelwal | Director | 18-Jan-2016 | Current |
| Kali Khandelwal | Director | 05-Mar-2020 | Current |
| Manju Khandelwal | Director | 18-Feb-2020 | Current |
| Pranita Khandelwal | Director | 18-Feb-2020 | Current |
Financial Performance of Safpure Lifesciences.
Safpure Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 122.99% increase. The company also saw a substantial improvement in profitability, with a 268.8% increase in profit. The company's net worth Soared by an impressive increase of 68.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Safpure Lifesciences?
In 2023, Safpure Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rasik Remedies Private LimitedActive 15 years 5 monthsGaurav Khandelwal, Sourabh Khandelwal and 1 more are mutual person
- Shri Shyam Prime Commodities Private LimitedActive 12 years 8 months
Gaurav Khandelwal and Sourabh Khandelwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Feb 2022 | ₹3.00 Cr | Open |
How Many Employees Work at Safpure Lifesciences?
Unlock and access historical data on people associated with Safpure Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safpure Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safpure Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
